Efficacy and safety of abacavir/lamivudine plus rilpivirine as a first-line regimen in treatment-naïve HIV-1 infected adults

Efficacy and safety of abacavir/lamivudine plus rilpivirine as a first-line regimen in treatment-naïve HIV-1 infected adults

Abstract Background The anti-retroviral combination of abacavir/lamivudine plus rilpivirine (ABC/3TC/RPV) is not recommended by international guidelines as the first-line regimen. However, it is potent, well-tolerated, and affordable, especially in resource-limited settings. This study evaluates the...

Full description

Bibliographic Details
Main Authors: Sharlene Ho, Joshua Guoxian Wong, Oon Tek Ng, Cheng Chuan Lee, Yee Sin Leo, David Chien Boon Lye, Chen Seong Wong
Format: Article
Language:English
Published: BMC 2020-05-01
Series:AIDS Research and Therapy
Subjects:
Abacavir
 Rilpivirine
Antiretroviral
Treatment-naïve
HIV
Online Access:http://link.springer.com/article/10.1186/s12981-020-00272-5

Internet

http://link.springer.com/article/10.1186/s12981-020-00272-5

Similar Items